Navigation Links
Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
Date:5/17/2010

'john.mattio@hcinternational.net' onClick="var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='93917079';s.tl(this,'o','ExternalLink');">john.mattio@hcinternational.net Web: http://www.hcinternational.net BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS March 31, December 31, 2010 2009 (Unaudited) (Audited) ASSETS Current Assets Cash and cash equivalents $8,642,418 $8,577,704 Accounts receivable 20,837,401 19,803,434 Inventories 564,955 340,078 Prepaid expenses and other receivables 1,487,143 1,500,327 Total Current Assets 31,531,917 30,221,543 Deposits 877,693 1,316,328 Property, plant and equipment, net 5,202,236 4,340,917 Intangible assets, net 11,314,977 11,131,681 Total Assets $48,926,823 $47,010,469 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable and accrued expenses $4,005,676 $3,559,281 Value-added tax payable 628,908 1,050,051 Income tax payable 920,079 1,481,266 Total Current Liabilities 5,554,663 6,090,598 Commitment and contingencies Stockholders' Equity Series B, convertible preferred stock, $0.001 par value, 5,000,000 shares authorized, 1,467,317 and 3
'/>"/>
SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
2. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
3. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
4. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
6. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
7. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
8. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
10. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
11. Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , September 16, 2014 BCC ... MARKET FOR STEM CELLS , the global market for ... billion by 2018, with a five-year compound annual growth ... witnessed in the Americas with growth projections of $2.2 ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other ...
(Date:9/15/2014)... Cancer Immunotherapy Market : ... Therapies is a new market research report announced ... principal types of therapeutics that have become the ... immunotherapy (which is often called "immuno-oncology") in recent ... cellular immunotherapy. , The regular use of ...
(Date:9/15/2014)... made of carbon nanotubes is neat, but Rice University scientists ... nanotubes in new fibers created at Rice line up like ... chemist Angel Mart and his colleagues. , The tricky bit, ... in the journal ACS Nano , is keeping the ... fiber. , Left to their own devices, carbon nanotubes form ...
(Date:9/15/2014)... 15, 2014 Research and Markets has ... by Product, by Services, by Technology, by Application - Global ... Whole Exome Sequencing (WES) is next-generation technology used for ... exon. The exome, which is the total of all exons ... and is actually converted into proteins after translation. It is ...
Breaking Biology Technology:Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3
... ON, April 11 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated products ... conducted on two of its,anti-cancer drugs, nimotuzumab and ... Cancer Research (AACR) Annual Meeting held from,April 12-16, ...
... Corp. (OTC Bulletin Board: "PWSF") has entered into ... held Delaware,corporation. Pursuant to the terms of the ... of Powersafe in exchange for,approximately 31,500,00 shares of ... and reserved for the exercise of options and,conversion ...
... 11 , - Newly Established Organization Presents ... Biotech Oncology Research & Development (ORD), a unit ... will announce,results from studies of three innovative compounds--Hdm2, ... for Cancer Research (AACR),2008 Annual Meeting., "ORD ...
Cached Biology Technology:YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING 2YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING 3Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification 2Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 2Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 3Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 4Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 5
(Date:9/15/2014)... INDIANAPOLIS -- Adding a common epilepsy drug to a ... fewer side effects. Moreover, the combination can reduce the ... to a team of pain researchers at Indiana University. ... patients with neuropathic pain, a difficult-to-treat condition often felt ... tissue damage. , "There is a huge unmet need ...
(Date:9/15/2014)... researchers have found "the most famous wheat gene," a ... to transfer valuable genes from other plants ... to develop wheat varieties with the disease- and pest-resistance ... tools that can reduce crop losses and pesticide use ... Genetically Modified Organisms, or GMOs., "The real exciting part ...
(Date:9/15/2014)... Conditions on Earth for the first 500 million years ... the present day, complete with oceans, continents and active ... geologic eon, called the Hadean, has gained substantial new ... that formed more than 4 billion years ago with ... as a possible geological analog for early Earth. , ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2WSU researchers find 'most famous wheat gene' 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... Eighty percent of American voters favor national standards that ... la carte foods sold in U.S. schools and encourage the ... a new poll commissioned by the Kids, Safe & Healthful ... and the Robert Wood Johnson Foundation. The U.S. ...
... this month on ecological changes at 26 global research sites ... in the high mountains west of the city -- indicates ... most sensitive to changes in climate. The six ... The papers were tied to data gathered at sites ...
... Academy of Sciences will host the Fifth Annual ... design of oligosaccharides and proteins for materials and ... on the following areas: (1) synthetic and biosynthetic ... these macromolecules in materials science and glycobiology, (2) ...
Cached Biology News:Poll shows strong voter support for school nutrition standards 2Poll shows strong voter support for school nutrition standards 3CU research shows warming climate threatens ecology at mountain research site west of Boulder 2CU research shows warming climate threatens ecology at mountain research site west of Boulder 3
... IEF cell is an apparatus dedicated to ... or agarose slab gels. The cell includes ... casting tray, 5 glass plates, 50 sheets ... sample templates, and instructions. Dimensions are 21 ...
... The Biomek FX provides complete ... applications. With 96-, 384-, ... heads in either single or ... FX offers maximum speed and ...
BD Falcon, microtest ELISA plate 96 well flat-bottom, clear. Polystyrene, nonsterile, no lid (25/sp, 100/ca) Packaging: 25 / pack, 100 / case ...
... a convenient method to probe conformational changes in ... Thus, the kit may be used to determine ... transport substrates for MDR1. Because UIC2 binding is ... the MDR1 Shift Assay can be utilized for ...
Biology Products: